Regulation of AKT gene expression by cisplatin

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 756-760

  Zhang, Jun ^a   Zhang, Ling Li ^a   Shen, Lei ^a   Xu, Xi Ming ^a   Yu, Hong Gang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

AKT; Chemoresistance; Colon cancer; Reactive oxygen species

Indexed keywords

CISPLATIN; JANUS KINASE 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CHEMOSENSITIVITY; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDCUTION; UPREGULATION; WESTERN BLOTTING;

EID: 84872746297     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1132     Document Type: Article

References (25)

1. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ and Nikiforova MN: The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med 133: 1600-1606, 2009.
2. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M and Kaina B: Long-term activation of SAPK/JNK, p38 kinase and Fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 112: 974-985, 2004.
3. Sánchez-Perez I, Murguía JR and Perona R: Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16: 533-540, 1998.
4. Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325-6332, 2007.
5. Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
6. Toker A and Yoeli-Lerner M: Akt signaling and cancer: surviving but not moving on. Cancer Res 66: 3963-3966, 2006.
7. Bellacosa A, Kumar CC, Di Cristofano A and Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94: 29-86, 2005.
8. Deng R, Tang J, Xie BF, Feng GK, Huang YH, Liu ZC and Zhu XF: SYUNZ-16, a newly synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer 127: 220-229, 2010.
9. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int JCancer 122: 433-443, 2008.
10. Yang X, Fraser M, Moll UM, Basak A and Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136, 2006.
11. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088, 2003.
12. Pellegrini S and Dusanter-Fourt I: The structure, regulation and function of the Janus kinases (JAKs) and the signal transducers and activators of transcription (STATs). Eur J Biochem 248: 615-633, 1997.
13. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D and Sebti SM: Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24: 3236-3245, 2005.
14. Martindale JL and Holbrook NJ: Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 192: 1-15, 2002.
15. Park S, Kim D, Kaneko S, Szewczyk KM, Nicosia SV, Yu H, Jove R and Cheng JQ: Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J Biol Chem 280: 38932-38941, 2005.
16. Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, JinYW, Kim CS and Nam SY: Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 11: 2518-2525, 2005.
17. Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98: 10983-10985, 2001.
18. Ruggero D and Sonenberg N: The Akt of translational control. Oncogene 24: 7426-7434, 2005.
19. Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, et al: AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 10: 975-987, 2005.
20. Huang HL, Fang LW, Lu SP, Chou CK, Luh TY and Lai MZ: DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation. Oncogene 22: 8168-8177, 2003.
21. Antico Arciuch VG, Galli S, Franco MC, Lam PY, Cadenas E, Carreras MC and Poderoso JJ: Akt1 intramitochondrial cycling is a crucial step in the redox modulation of cell cycle progression. PLoS One 4: e7523, 2009.
22. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, et al: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444, 2007.
23. Liu X, Shi Y, Han EK, Chen Z, Rosenberg SH, Giranda VL, Luo Y and Ng SC: Down regulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 3: 278-286, 2001.
24. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21: 7611-7618, 2002.
25. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, et al: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20: 2499-2513, 2001.